{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:26:07Z","timestamp":1789471567856,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Biomedical Advanced Research and Development Authority"},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.057","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T23:25:41Z","timestamp":1467156341000},"page":"4188-4195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity"],"prefix":"10.1016","volume":"34","author":[{"given":"Juan C.","family":"Amador-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther D.","family":"Valerdi-Madrigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo I.","family":"Dom\u00ednguez-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev A.","family":"Sirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Arciniega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.057_b0005","first-page":"13","article-title":"Anthrax pathogenesis and host response","volume":"225","author":"Hanna","year":"1998","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1164\/rccm.201102-0209CI","article-title":"Anthrax infection","volume":"184","author":"Sweeney","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.06.057_b0015","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.057_b0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2016.06.057_b0025","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.06.057_b0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/iai.49.2.291-297.1985","article-title":"Demonstration of a capsule plasmid in Bacillus anthracis","volume":"49","author":"Green","year":"1985","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0035","first-page":"557","article-title":"Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110MDa and 60MDa plasmids","volume":"132","author":"Uchida","year":"1986","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0040","first-page":"446","article-title":"The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action","volume":"44","author":"Keppie","year":"1963","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/iai.39.1.371-376.1983","article-title":"Evidence for plasmid-mediated toxin production in Bacillus anthracis","volume":"39","author":"Mikesell","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.057_b0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mam.2009.06.003","article-title":"Membrane translocation by anthrax toxin","volume":"30","author":"Collier","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2016.06.057_b0060","doi-asserted-by":"crossref","first-page":"C1402","DOI":"10.1152\/ajpcell.00582.2004","article-title":"ATR\/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis\u2019 three sites of entry: implications for the pathogenesis of anthrax infection","volume":"288","author":"Bonuccelli","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0065","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.057_b0070","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.89.21.10277","article-title":"Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin","volume":"89","author":"Klimpel","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.057_b0075","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"Brey","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2016.06.057_b0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1021\/bi015860m","article-title":"Stoichiometry of anthrax toxin complexes","volume":"41","author":"Mogridge","year":"2002","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.vaccine.2016.06.057_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1574-695X.2011.00782.x","article-title":"Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo","volume":"62","author":"Little","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2016.06.057_b0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20061891","article-title":"Manipulation of host signalling pathways by anthrax toxins","volume":"402","author":"Turk","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2016.06.057_b0100","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/IAI.73.9.5685-5696.2005","article-title":"Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation","volume":"73","author":"Kudva","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0105","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1016\/j.vaccine.2004.04.036","article-title":"Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis","volume":"22","author":"Whiting","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.057_b0110","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/S0021-9258(17)38364-3","article-title":"Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process","volume":"261","author":"Friedlander","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.06.057_b0115","first-page":"17","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biol J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.06.057_b0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-065X.2010.00969.x","article-title":"Progress and novel strategies in vaccine development and treatment of anthrax","volume":"239","author":"Chitlaru","year":"2011","journal-title":"Immunol Rev"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2016.06.057_b0125","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.057_b0130","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0135","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/IAI.66.7.3447-3448.1998","article-title":"Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis","volume":"66","author":"Singh","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0140","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.057_b0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2016.06.057_b0150","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.9777","article-title":"Is new always better than old?: the development of human vaccines for anthrax","volume":"5","author":"Baillie","year":"2009","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2016.06.057_b0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0168-1656(96)01569-6","article-title":"Thermostabilization of protective antigen \u2013 the binding component of anthrax lethal toxin","volume":"50","author":"Radha","year":"1996","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2016.06.057_b0160","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbrc.2004.08.020","article-title":"Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes","volume":"322","author":"Singh","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0165","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1023\/A:1015929109894","article-title":"Stability of protein pharmaceuticals","volume":"6","author":"Manning","year":"1989","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2016.06.057_b0170","first-page":"307","article-title":"The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation","volume":"10","author":"Cleland","year":"1993","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2016.06.057_b0175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/IAI.00863-12","article-title":"Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen","volume":"81","author":"Verma","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CVI.00267-10","article-title":"Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay","volume":"18","author":"Castel\u00e1n-Vega","year":"2011","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"key":"10.1016\/j.vaccine.2016.06.057_b0185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","article-title":"Development of validated stability-indicating assay methods \u2013 critical review","volume":"28","author":"Bakshi","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2016.06.057_b0190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.057_b0195","first-page":"157","article-title":"Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice","volume":"32","author":"Pombo","year":"2004","journal-title":"Biol J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.06.057_b0200","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2004.10.014","article-title":"Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants","volume":"23","author":"Berthold","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.057_b0205","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/CVI.00046-13","article-title":"Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay","volume":"20","author":"Lu","year":"2013","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"key":"10.1016\/j.vaccine.2016.06.057_b0210","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/CVI.00145-10","article-title":"Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays","volume":"17","author":"Brady","year":"2010","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"key":"10.1016\/j.vaccine.2016.06.057_b0215","unstructured":"World Health Organization. Temperature sensitivity of vaccines. WHO; 2006. <http:\/\/www.who.int\/immunization\/documents\/WHO_IVB_06.10\/en\/> [accessed February 3, 2016]."},{"key":"10.1016\/j.vaccine.2016.06.057_b0220","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0006-291X(02)02049-1","article-title":"Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis","volume":"296","author":"Singh","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2007.04.030","article-title":"Unfolding transitions of Bacillus anthracis protective antigen","volume":"465","author":"Chalton","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.vaccine.2016.06.057_b0230","first-page":"751091","article-title":"Thermal aggregation of recombinant protective antigen: aggregate morphology and growth rate","volume":"2013","author":"Belton","year":"2013","journal-title":"J Biophys Hindawi Publ Corp Online"},{"key":"10.1016\/j.vaccine.2016.06.057_b0235","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jps.24295","article-title":"Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants","volume":"104","author":"Hassett","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2016.06.057_b0240","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4161\/hv.25852","article-title":"Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine","volume":"9","author":"Iyer","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2016.06.057_b0245","first-page":"50","article-title":"Stability versus potency testing: the madness is in the method","volume":"12","author":"Kupiec","year":"2008","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.vaccine.2016.06.057_b0250","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/iai.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0255","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.057_b0260","first-page":"236","article-title":"Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines","volume":"39","author":"Jim\u00e9nez-Alberto","year":"2011","journal-title":"Biol J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2016.06.057_b0265","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.8.3.313","article-title":"Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement","volume":"8","author":"Hendriksen","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.06.057_b0270","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jps.23422","article-title":"Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine","volume":"102","author":"D\u2019Souza","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2016.06.057_b0275","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"key":"10.1016\/j.vaccine.2016.06.057_b0280","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/CVI.00701-15","article-title":"Mechanistic analysis of the effect of deamidation on the immunogenicity of anthrax protective antigen","volume":"23","author":"Verma","year":"2016","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"key":"10.1016\/j.vaccine.2016.06.057_b0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1359-0294(00)00057-1","article-title":"Globular protein gelation","volume":"5","author":"Gosal","year":"2000","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.vaccine.2016.06.057_b0290","doi-asserted-by":"crossref","first-page":"12409","DOI":"10.1073\/pnas.221463198","article-title":"Deamidation of human proteins","volume":"98","author":"Robinson","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.057_b0295","doi-asserted-by":"crossref","first-page":"44258","DOI":"10.1074\/jbc.M405648200","article-title":"Deamidation affects structural and functional properties of human alphaA-crystallin and its oligomerization with alphaB-crystallin","volume":"279","author":"Gupta","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.06.057_b0300","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1110\/ps.035410.108","article-title":"Deamidation destabilizes and triggers aggregation of a lens protein, betaA3-crystallin","volume":"17","author":"Takata","year":"2008","journal-title":"Protein Sci Publ Protein Soc"},{"key":"10.1016\/j.vaccine.2016.06.057_b0305","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/jps.1165","article-title":"Controlling deamidation rates in a model peptide: effects of temperature, peptide concentration, and additives","volume":"90","author":"Stratton","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2016.06.057_b0310","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/385833a0","article-title":"Crystal structure of the anthrax toxin protective antigen","volume":"385","author":"Petosa","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.057_b0315","first-page":"475","article-title":"Biophysical characterisation of thermal-induced precipitates of recombinant anthrax protective antigen: evidence for kinetically trapped unfolding domains in solid-state","volume":"82","author":"Ganesan","year":"2012","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft F\u00fcr Pharm Verfahrenstechnik EV"},{"key":"10.1016\/j.vaccine.2016.06.057_b0320","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised tripartite guideline quality of biotechnological products: stability testing of biotechnological\/biological products Q5C; 1995."},{"key":"10.1016\/j.vaccine.2016.06.057_b0325","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised tripartite guideline stability testing of new drug substances and products Q1A(R2); 2003."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:22:24Z","timestamp":1759400544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":65,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16305084"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}